Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles

ACS Nano

Volumn 9, Issue 2, 2015, Pages 1581-1591

  Cohen, Zvi R ^a   Ramishetti, Srinivas ^b   Peshes Yaloz, Naama ^a   Goldsmith, Meir ^b   Wohl, Anton ^a   Zibly, Zion ^a   Peer, Dan ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

glioma; hyaluronan; lipid based nanoparticles; RNAi

Indexed keywords

BRAIN; CELL CULTURE; CELL DEATH; CEREBROSPINAL FLUID; CONTROLLED DRUG DELIVERY; GRAFTING (CHEMICAL); MAMMALS; NANOPARTICLES; PROTEOMICS; RNA; SHEAR FLOW; TARGETED DRUG DELIVERY; TUMORS;

BLOOD-BRAIN BARRIER; GLIOBLASTOMA MULTIFORME; GLIOMA; HYALURONAN; RNAI; SMALL INTERFERING RNA; THERAPEUTIC MODALITY; THERAPEUTIC TARGETS;

HYALURONIC ACID;

CELL CYCLE PROTEIN; DRUG CARRIER; HERMES ANTIGEN; HYALURONIC ACID; LIPID; NANOPARTICLE; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL; BAGG ALBINO MOUSE; CANCER GRADING; CELL DEATH; CELL TRANSFORMATION; CHEMISTRY; DEFICIENCY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; RNAI THERAPEUTICS; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; BIOLOGICAL TRANSPORT; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; HYALURONIC ACID; LIPIDS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASM GRADING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNAI THERAPEUTICS;

EID: 84923459414     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn506248s     Document Type: Article

References (52)

1. Lacroix, M.; Abi-Said, D.; Fourney, D. R.; Gokaslan, Z. L.; Shi, W.; DeMonte, F.; Lang, F. F.; McCutcheon, I. E.; Hassenbusch, S. J.; Holland, E. A Multivariate Analysis of 416 Patients with Glioblastoma Multiforme: Prognosis, Extent of Resection, and Survival J. Neurosurg. 2001, 95, 190-198
2. Saito, N.; Fu, J.; Zheng, S.; Yao, J.; Wang, S.; Liu, D. D.; Yuan, Y.; Sulman, E. P.; Lang, F. F.; Colman, H. A High Notch Pathway Activation Predicts Response to Gamma Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells Stem Cells 2014, 32, 301-312
3. Berghoff, A. S.; Kiesel, B.; Widhalm, G.; Rajky, O.; Ricken, G.; Wohrer, A.; Dieckmann, K.; Filipits, M.; Brandstetter, A.; Weller, M., Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Glioblastoma. Neuro Oncol. 2014; pii: nou307.
4. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O. D.; Zanella, F.; Reulen, H. J.; Group, A. L.-G. S. Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial Lancet Oncol. 2006, 7, 392-401
5. Senft, C.; Bink, A.; Franz, K.; Vatter, H.; Gasser, T.; Seifert, V. Intraoperative MRI Guidance and Extent of Resection in Glioma Surgery: A Randomised, Controlled Trial Lancet Oncol. 2011, 12, 997-1003
6. Westphal, M.; Yla-Herttuala, S.; Martin, J.; Warnke, P.; Menei, P.; Eckland, D.; Kinley, J.; Kay, R.; Ram, Z.; Group, A. S. Adenovirus-Mediated Gene Therapy with Sitimagene Ceradenovec Followed by Intravenous Ganciclovir for Patients with Operable High-Grade Glioma (ASPECT): A Randomised, Open-Label, Phase 3 Trial Lancet Oncol. 2013, 14, 823-833
7. Sampson, J. H.; Archer, G.; Pedain, C.; Wembacher-Schroder, E.; Westphal, M.; Kunwar, S.; Vogelbaum, M. A.; Coan, A.; Herndon, J. E.; Raghavan, R. Poor Drug Distribution as a Possible Explanation for the Results of the PRECISE Trial J. Neurosurg. 2010, 113, 301-309
8. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760
9. Lynch, I.; Dawson, K. A.; Linse, S. Detecting Cryptic Epitopes Created by Nanoparticles Science's STKE 2006, pe14
10. Hernandez-Pedro, N. Y.; Rangel-Lopez, E.; Magana-Maldonado, R.; de la Cruz, V. P.; del Angel, A. S.; Pineda, B.; Sotelo, J. Application of Nanoparticles on Diagnosis and Therapy in Gliomas BioMed. Res. Int. 2013, 351031
11. Chen, H.; Qin, Y.; Zhang, Q.; Jiang, W.; Tang, L.; Liu, J.; He, Q. Lactoferrin Modified Doxorubicin-Loaded Procationic Liposomes for the Treatment of Gliomas Eur. J. Pharma Sci. 2011, 44, 164-173
12. Gong, W.; Wang, Z.; Liu, N.; Lin, W.; Wang, X.; Xu, D.; Liu, H.; Zeng, C.; Xie, X.; Mei, X. Improving Efficiency of Adriamycin Crossing Blood Brain Barrier by Combination of Thermosensitive Liposomes and Hyperthermia Biol. Pharm. Bull. 2011, 34, 1058-1064
13. Qin, Y.; Chen, H.; Zhang, Q.; Wang, X.; Yuan, W.; Kuai, R.; Tang, J.; Zhang, L.; Zhang, Z.; Zhang, Q. Liposome Formulated with TAT-Modified Cholesterol for Improving Brain Delivery and Therapeutic Efficacy on Brain Glioma in Animals Int. J. Pharm. 2011, 420, 304-312
14. Tezcan, G.; Tunca, B.; Bekar, A.; Budak, F.; Sahin, S.; Cecener, G.; Egeli, U.; Taskapilioglu, M. O.; Kocaeli, H.; Tolunay, S. Olea Europaea Leaf Extract Improves the Treatment Response of GBM Stem Cells by Modulating miRNA Expression Am. J. Cancer Res. 2014, 4, 572-590
15. Hong, X. Y.; Wang, J.; Li, Z. AGR2 Expression is Regulated by HIF-1 and Contributes to Growth and Angiogenesis of Glioblastoma Cell Biochem. Biophys. 2013, 67, 1487-1495
16. Platt, V. M.; Szoka, F. C., Jr. Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, A Hyaluronan Receptor Mol. Pharmaceutics 2008, 5, 474-486
17. Eliaz, R. E.; Szoka, F. C., Jr. Liposome-Encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44-Overexpressing Tumor Cells Cancer Res. 2001, 61, 2592-2601
18. Peer, D.; Margalit, R. Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in Syngeneic and Human Xenograft Mouse Tumor Models Neoplasia 2004, 6, 343-353
19. Peer, D.; Margalit, R. Loading Mitomycin C Inside Long Circulating Hyaluronan Targeted Nano-Liposomes Increases its Antitumor Activity in Three Mice Tumor Models Int. J. Cancer 2004, 108, 780-789
20. Poon, Z.; Lee, J. B.; Morton, S. W.; Hammond, P. T. Controlling In Vivo Stability and Biodistribution in Electrostatically Assembled Nanoparticles for Systemic Delivery Nano Lett. 2011, 11, 2096-2103
21. Rivkin, I.; Cohen, K.; Koffler, J.; Melikhov, D.; Peer, D.; Margalit, R. Paclitaxel-Clusters Coated with Hyaluronan as Selective Tumor-Targeted Nanovectors Biomaterials 2010, 31, 7106-7114
22. Cohen, K.; Emmanuel, R.; Kisin-Finfer, E.; Shabat, D.; Peer, D. Modulation of Drug Resistance in Ovarian Adenocarcinoma using Chemotherapy Entrapped in Hyaluronan-Grafted Nanoparticle Clusters ACS Nano 2014, 8, 2183-2195
23. Mizrahy, S.; Goldsmith, M.; Leviatan-Ben-Arye, S.; Kisin-Finfer, E.; Redy, O.; Srinivasan, S.; Shabat, D.; Godin, B.; Peer, D. Tumor Targeting Profiling of Hyaluronan-Coated Lipid Based-Nanoparticles Nanoscale 2014, 6, 3742-3752
24. Mizrahy, S.; Raz, S. R.; Hasgaard, M.; Liu, H.; Soffer-Tsur, N.; Cohen, K.; Dvash, R.; Landsman-Milo, D.; Bremer, M. G.; Moghimi, S. M. Hyaluronan-Coated Nanoparticles: The Influence of the Molecular Weight on CD44-Hyaluronan Interactions and on the Immune Response J. Controlled Release 2011, 156, 231-238
25. Bachar, G.; Cohen, K.; Hod, R.; Feinmesser, R.; Mizrachi, A.; Shpitzer, T.; Katz, O.; Peer, D. Hyaluronan-Grafted Particle Clusters Loaded with Mitomycin C as Selective Nanovectors for Primary Head and Neck Cancers Biomaterials 2011, 32, 4840-4848
26. Yao, Y. D.; Sun, T. M.; Huang, S. Y.; Dou, S.; Lin, L.; Chen, J. N.; Ruan, J. B.; Mao, C. Q.; Yu, F. Y.; Zeng, M. S. Targeted Delivery of PLK1-SiRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis Sci. Transl. Med. 2012, 4, 130ra48
27. Cheng, M. W.; Wang, B. C.; Weng, Z. Q.; Zhu, X. W. Clinicopathological Significance of Polo-Like Kinase 1 (PLK1) Expression in Human Malignant Glioma Acta Histochem. 2012, 114, 503-509
28. Signore, M.; Pelacchi, F.; di Martino, S.; Runci, D.; Biffoni, M.; Giannetti, S.; Morgante, L.; De Majo, M.; Petricoin, E. F.; Stancato, L. Combined PDK1 and CHK1 Inhibition is Required to Kill Glioblastoma Stem-Like Cells In Vitro and In Vivo Cell Death Dis. 2014, 5, e1223
29. Pyko, I. V.; Nakada, M.; Sabit, H.; Teng, L.; Furuyama, N.; Hayashi, Y.; Kawakami, K.; Minamoto, T.; Fedulau, A. S.; Hamada, J. Glycogen Synthase Kinase 3Beta Inhibition Sensitizes Human Glioblastoma Cells to Temozolomide by Affecting O6-Methylguanine DNA Methyltransferase Promoter Methylation via c-Myc Signaling Carcinogenesis 2013, 34, 2206-2217
30. Rungta, R. L.; Choi, H. B.; Lin, P. J.; Ko, R. W.; Ashby, D.; Nair, J.; Manoharan, M.; Cullis, P. R.; Macvicar, B. A. Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain Mol. Ther. Nucleic Acids 2013, 2, e136
31. Peer, D.; Park, E. J.; Morishita, Y.; Carman, C. V.; Shimaoka, M. Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target Science 2008, 319, 627-630
32. Mizrahy, S.; Peer, D. Polysaccharides as Building Blocks for Nanotherapeutics Chem. Soc. Rev. 2012, 41, 2623-2640
33. Ganoth, A.; Merimi, K. C.; Peer, D. Overcoming Multidrug Resistance with Nanomedicines Expert Opin. Drug Deliv. 2014, 1-16
34. Drinberg, V.; Bitcover, R.; Rajchenbach, W.; Peer, D. Modulating Cancer Multidrug Resistance by Sertraline in Combination with a Nanomedicine Cancer Lett. 2014, 354, 290-298
35. Shulman, Z.; Alon, R. Chapter 14. Real-Time In Vitro Assays for Studying the Role of Chemokines in Lymphocyte Transendothelial Migration Under Physiologic Flow Conditions Methods Enzymol. 2009, 461, 311-332
36. Kuroda, J.; Kuratsu, J.; Yasunaga, M.; Koga, Y.; Kenmotsu, H.; Sugino, T.; Matsumura, Y. Antitumor Effect Of NK012, A 7-Ethyl-10-Hydroxycamptothecin-Incorporating Polymeric Micelle, on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan Hydrochloride in Combination with Bevacizumab Clin. Cancer Res. 2010, 16, 521-529
37. Li, C.; Zhou, Y.; Peng, X.; Du, L.; Tian, H.; Yang, G.; Niu, J.; Wu, W. Sulforaphane Inhibits Invasion Via Activating ERK1/2 Signaling in Human Glioblastoma U87MG and U373MG Cells PLoS One 2014, 9, e90520
38. Kumar, P.; Wu, H.; McBride, J. L.; Jung, K. E.; Kim, M. H.; Davidson, B. L.; Lee, S. K.; Shankar, P.; Manjunath, N. Transvascular Delivery of Small Interfering RNA to the Central Nervous System Nature 2007, 448, 39-43
39. Sakurai, Y.; Hatakeyama, H.; Akita, H.; Harashima, H. Improvement of Doxorubicin Efficacy Using Liposomal Anti-Polo-Like Kinase 1 siRNA in Human Renal Cell Carcinomas Mol. Pharmaceutics 2014, 11, 2713-2719
40. Cho, D. Y.; Lin, S. Z.; Yang, W. K.; Lee, H. C.; Hsu, D. M.; Lin, H. L.; Chen, C. C.; Liu, C. L.; Lee, W. Y.; Ho, L. H. Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme Cell Transplant 2013, 22, 731-739
41. Denysenko, T.; Gennero, L.; Roos, M. A.; Melcarne, A.; Juenemann, C.; Faccani, G.; Morra, I.; Cavallo, G.; Reguzzi, S.; Pescarmona, G. Glioblastoma Cancer Stem Cells: Heterogeneity, Microenvironment and Related Therapeutic Strategies Cell Biochem. Funct. 2010, 28, 343-351
42. Phillips, J. J. Novel Therapeutic Targets in the Brain Tumor Microenvironment Oncotarget 2012, 3, 568-575
43. Wainwright, D. A.; Chang, A. L.; Dey, M.; Balyasnikova, I. V.; Kim, C. K.; Tobias, A.; Cheng, Y.; Kim, J. W.; Qiao, J.; Zhang, L. Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors Clin. Cancer Res. 2014, 20, 5290-5301
44. Yi, N.; Oh, B.; Kim, H. A.; Lee, M. Combined Delivery of BCNU and VEGF siRNA Using Amphiphilic Peptides for Glioblastoma J. Drug Target 2014, 22, 156-164
45. Low, S. Y.; Ho, Y. K.; Too, H. P.; Yap, C. T.; Ng, W. H. Microrna as Potential Modulators in Chemoresistant High-Grade Gliomas J. Clin. Neurosci. 2014, 21, 395-400
46. Karpel-Massler, G.; Westhoff, M. A.; Zhou, S.; Nonnenmacher, L.; Dwucet, A.; Kast, R. E.; Bachem, M. G.; Wirtz, C. R.; Debatin, K. M.; Halatsch, M. E. Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells Mol. Cancer Ther. 2013, 12, 1783-1795
47. Goldberg, L.; Ocherashvilli, A.; Daniels, D.; Last, D.; Cohen, Z. R.; Tamar, G.; Kloog, Y.; Mardor, Y. Salirasib (Farnesyl Thiosalicylic Acid) for Brain Tumor Treatment: A Convection-Enhanced Drug Delivery Study in Rats Mol. Cancer Ther. 2008, 7, 3609-3616
48. Jayaraman, M.; Ansell, S. M.; Mui, B. L.; Tam, Y. K.; Chen, J.; Du, X.; Butler, D.; Eltepu, L.; Matsuda, S.; Narayanannair, J. K. Maximizing The Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo Angew. Chem., Int. Ed. 2012, 51, 8529-8533
49. Weinstein, S.; Emmanuel, R.; Jacobi, A. M.; Abraham, A.; Behlke, M. A.; Sprague, A. G.; Novobrantseva, T. I.; Nagler, A.; Peer, D. RNA Inhibition Highlights Cyclin D1 as a Potential Therapeutic Target for Mantle Cell Lymphoma PLoS One 2012, 7, e43343
50. Landesman-Milo, D.; Goldsmith, M.; Leviatan Ben-Arye, S.; Witenberg, B.; Brown, E.; Leibovitch, S.; Azriel, S.; Tabak, S.; Morad, V.; Peer, D. Hyaluronan Grafted Lipid-Based Nanoparticles as Rnai Carriers for Cancer Cells Cancer Lett. 2013, 334, 221-227
51. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V. Potent and Persistent in Vivo Anti-HBV Activity of Chemically Modified siRNAs Nat. Biotechnol. 2005, 23, 1002-1007
52. Leuschner, F.; Dutta, P.; Gorbatov, R.; Novobrantseva, T. I.; Donahoe, J. S.; Courties, G.; Lee, K. M.; Kim, J. I.; Markmann, J. F.; Marinelli, B. Therapeutic siRNA Silencing in Inflammatory Monocytes in Mice Nat. Biotechnol. 2011, 29, 1005-1010